- Categories: Pipeline
- Time of issue:2018-01-25 00:00:00
PD-L1 is a potential biomaker for the development of PD-1/PD-L1 targeted therapies. It has been shown that patients with high levels of PD-L1 expression has high probability of benefiting from checkpoint inhibitor treatment. Currently there are several FDA approved PD-L1 companion diagnostic kit for the IHC detection of PD-L1 expression in tumor cells (TC) or immune cells (IC). MabSpace has developed its own in house companion diagnostic antibodies for the detection of PD-L1 expression using either IHC or Elisa based methods.
PD-L1 staining in gastric cancer
Scan the QR code to read on your phone